OvaScience SM, (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of female fertility treatments, today provided an update on its product pipeline and commercial plans, which are based on its egg precursor cell (EggPC SM) technology platform. OvaScience expects to commercialize AUGMENT SM in international in vitro fertilization (IVF) clinics in 2014 and to launch its newest potential fertility treatment, OvaPrime SM, in 2015.
OvaScience plans to introduce its AUGMENT Centers of Excellence (ACE) access program into international IVF clinics for physicians to gain experience using AUGMENT and to generate data. In 2014, the Company expects to establish ACE clinics in at least four international regions, which the Company anticipates will result in 40 to 60 AUGMENT cycles this year. By year end, OvaScience expects to transition these ACE clinics to commercial centers.
“Accessing the international fertility markets represents the largest commercial opportunity for OvaScience,” said Michelle Dipp, M.D., Ph.D., Chief Executive Officer of OvaScience. “ACE will provide key opinion leaders in IVF clinics with experience using AUGMENT and enable us to gather further data. We look forward to making AUGMENT available to patients in these regions of high unmet need.”
OvaPrime SM, the latest addition to OvaScience’s pipeline, is designed to boost a woman’s egg reserve using her own EggPCs. OvaScience will conduct further studies and continue product optimization in 2014 in anticipation of a commercial launch of OvaPrime in 2015.Recently, OvaScience established a collaboration with Intrexon Corporation to accelerate development of OvaTure SM, the Company’s potential next generation IVF treatment, which does not require hormone hyperstimulation. OvaScience also recently formed the OvaXon Joint Venture with Intrexon to create new applications to prevent inherited diseases for human and animal health. “Our proprietary EggPC technology platform continues to create new fertility treatments for women, such as OvaPrime,” said Arthur Tzianabos, Ph.D., Chief Science Officer of OvaScience. “In addition, we are leveraging the platform to develop innovative approaches in other areas, including the prevention of inherited diseases.”
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV